Company Media
-
Immuron reduces liver inflammation (Mar 2018, Nine Finance)
-
Immuron positive clinical trial results fight fatty liver disease (Mar 2018, Small Caps)
-
Shares in Australian pharma Immuron are going nuts (Mar 2018, Business Insider)
-
Immuron's IMM-124E shows encouraging action in mid-stage NASH study (Mar 2018, Seeking Alpha)
-
Immuron shares surge on demonstrating proof of concept for liver drug candidates (Mar 2018, Proactive Investors)
-
Results in: IMC's lead drug reduces major factor in liver inflammation (Mar 2018, Finfeed)
-
Blockbuster results from IMC's NASH liver therapy trials (Mar 2018, NextBiotech)
-
How do you recruit patients unaware of their disease (Clinical Leader)
-
Are these unsanitary things really that bad for you? (Oct 2017, Healthyway)
-
Immuron's fatty liver disease candidate advancing - 4 insights (Sept 2017, Becker's GI and Endoscopy)
-
In dash to NASH, Immuron targets the gut not the liver (Mar 2017, MedCity News)
-
2017 Bioshares Biotech Summit coverage - IMM-124E targets the gut and the microbiome (Bioshares)
-
Biotech tackles hospital infection (The Australian, Mar 2017)
-
Immuron to start search for partner or buyer of fatty liver therapeutics in Q1 2017 (Oct 2016, Proactive Investors - Merger Market)
-
Protect yourself from mosquito bites while traveling this summer (April 2016, Arizona Midday)
-
Healthy and safe travel products (April 2016, Good Day DC)
-
5 hot travel items (March 2016, What is Travelan and How Does it Work?)
